Physicians and clinical pharmacists should pay close attention to possible clinical symptoms such as muscle weakness, myalgia, backache and fatigue as well as rhabdomyolysis markers like elevated CPK, LDH, creatinine and serum myoglobin during newer-generation ASMs treatment to identify early warning signs and prevent any severe complications. This evidence concerns the gene PIK3C2A and rhabdomyolysis.